C4 THERAPEUTICS INC (CCCC) Fundamental Analysis & Valuation

NASDAQ:CCCC • US12529R1077

Current stock price

2.86 USD
+0.12 (+4.38%)
Last:

This CCCC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CCCC Profitability Analysis

1.1 Basic Checks

  • CCCC had negative earnings in the past year.
  • CCCC had a negative operating cash flow in the past year.
  • In the past 5 years CCCC always reported negative net income.
  • CCCC had a negative operating cash flow in each of the past 5 years.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • CCCC's Return On Assets of -29.24% is fine compared to the rest of the industry. CCCC outperforms 67.31% of its industry peers.
  • CCCC has a Return On Equity of -40.92%. This is in the better half of the industry: CCCC outperforms 67.89% of its industry peers.
Industry RankSector Rank
ROA -29.24%
ROE -40.92%
ROIC N/A
ROA(3y)-31.52%
ROA(5y)-28.17%
ROE(3y)-47.84%
ROE(5y)-41.87%
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K 4K

1.3 Margins

  • CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CCCC Health Analysis

2.1 Basic Checks

  • CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CCCC has been increased compared to 1 year ago.
  • The number of shares outstanding for CCCC has been increased compared to 5 years ago.
  • CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -1.42, we must say that CCCC is in the distress zone and has some risk of bankruptcy.
  • CCCC has a Altman-Z score of -1.42. This is comparable to the rest of the industry: CCCC outperforms 52.22% of its industry peers.
  • There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.42
ROIC/WACCN/A
WACC9.21%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • CCCC has a Current Ratio of 7.81. This indicates that CCCC is financially healthy and has no problem in meeting its short term obligations.
  • CCCC has a Current ratio of 7.81. This is in the better half of the industry: CCCC outperforms 70.21% of its industry peers.
  • A Quick Ratio of 7.81 indicates that CCCC has no problem at all paying its short term obligations.
  • CCCC has a Quick ratio of 7.81. This is in the better half of the industry: CCCC outperforms 70.79% of its industry peers.
Industry RankSector Rank
Current Ratio 7.81
Quick Ratio 7.81
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CCCC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.93% over the past year.
  • The Revenue has been growing slightly by 1.02% in the past year.
  • The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)9.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
Revenue 1Y (TTM)1.02%
Revenue growth 3Y4.95%
Revenue growth 5Y1.6%
Sales Q2Q%112.79%

3.2 Future

  • Based on estimates for the next years, CCCC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.03% on average per year.
  • CCCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 129.64% yearly.
EPS Next Y7.84%
EPS Next 2Y10.45%
EPS Next 3Y8.64%
EPS Next 5Y13.03%
Revenue Next Year-27.7%
Revenue Next 2Y-14.97%
Revenue Next 3Y-2.27%
Revenue Next 5Y129.64%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. CCCC Valuation Analysis

4.1 Price/Earnings Ratio

  • CCCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CCCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.45%
EPS Next 3Y8.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CCCC Dividend Analysis

5.1 Amount

  • CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CCCC Fundamentals: All Metrics, Ratios and Statistics

C4 THERAPEUTICS INC

NASDAQ:CCCC (4/8/2026, 9:45:52 AM)

2.86

+0.12 (+4.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners76.74%
Inst Owner Change0%
Ins Owners3.74%
Ins Owner Change53.32%
Market Cap279.08M
Revenue(TTM)35.95M
Net Income(TTM)-104.99M
Analysts85.71
Price Target11.8 (312.59%)
Short Float %15.57%
Short Ratio6.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.84%
Min EPS beat(2)-6.21%
Max EPS beat(2)41.9%
EPS beat(4)3
Avg EPS beat(4)15.15%
Min EPS beat(4)-6.21%
Max EPS beat(4)41.9%
EPS beat(8)5
Avg EPS beat(8)10.85%
EPS beat(12)7
Avg EPS beat(12)9.3%
EPS beat(16)9
Avg EPS beat(16)7.85%
Revenue beat(2)2
Avg Revenue beat(2)71.25%
Min Revenue beat(2)67.19%
Max Revenue beat(2)75.3%
Revenue beat(4)3
Avg Revenue beat(4)49.67%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)75.3%
Revenue beat(8)5
Avg Revenue beat(8)63.5%
Revenue beat(12)7
Avg Revenue beat(12)42.92%
Revenue beat(16)8
Avg Revenue beat(16)30.91%
PT rev (1m)2.53%
PT rev (3m)3.85%
EPS NQ rev (1m)-9.25%
EPS NQ rev (3m)6.05%
EPS NY rev (1m)0%
EPS NY rev (3m)14.22%
Revenue NQ rev (1m)7.63%
Revenue NQ rev (3m)44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.76
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.37
BVpS2.63
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.24%
ROE -40.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.52%
ROA(5y)-28.17%
ROE(3y)-47.84%
ROE(5y)-41.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.99%
Cap/Sales 1.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.81
Quick Ratio 7.81
Altman-Z -1.42
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)43.91%
Cap/Depr(5y)109.01%
Cap/Sales(3y)3.47%
Cap/Sales(5y)6.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
EPS Next Y7.84%
EPS Next 2Y10.45%
EPS Next 3Y8.64%
EPS Next 5Y13.03%
Revenue 1Y (TTM)1.02%
Revenue growth 3Y4.95%
Revenue growth 5Y1.6%
Sales Q2Q%112.79%
Revenue Next Year-27.7%
Revenue Next 2Y-14.97%
Revenue Next 3Y-2.27%
Revenue Next 5Y129.64%
EBIT growth 1Y10.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.85%
EBIT Next 3Y2.43%
EBIT Next 5YN/A
FCF growth 1Y-51.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.47%
OCF growth 3YN/A
OCF growth 5YN/A

C4 THERAPEUTICS INC / CCCC Fundamental Analysis FAQ

What is the fundamental rating for CCCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CCCC.


What is the valuation status of C4 THERAPEUTICS INC (CCCC) stock?

ChartMill assigns a valuation rating of 0 / 10 to C4 THERAPEUTICS INC (CCCC). This can be considered as Overvalued.


What is the profitability of CCCC stock?

C4 THERAPEUTICS INC (CCCC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CCCC stock?

The Earnings per Share (EPS) of C4 THERAPEUTICS INC (CCCC) is expected to grow by 7.84% in the next year.